Vir Biotechnology, Inc.
HealthcareNASDAQ:VIR · NASDAQ Global Select
+$0.09 today
Vol 1.11M · Avg 1.88M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-57.2%
avg 0.4%
ROIC
-50.9%
avg -29.7%
ROA
-43.7%
avg -24.7%
Analysis
ROA is currently the strongest return metric at -43.7% versus its period average of -24.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Marianne De Backer | President, CEO & Director | $2.03M | — | 57 | $286,650.00 | 0.17% |
Mark D. Eisner | Executive Vice President & Chief Medical Officer | $1.40M | — | 60 | $154,024.00 | 0.09% |
Jason O'Byrne | Executive Vice President & Chief Financial Officer | $984,468.00 | — | 57 | $160,115.00 | 0.09% |
Vanina De Verneuil | Executive Vice President, General Counsel & Corporate Secretary | $844,344.00 | — | 47 | $286,650.00 | 0.17% |
Lawrence Corey | Co-Founder & Scientific Advisor | $177,661.00 | — | 79 | — | — |
Louis J. Picker | Co-Founder & Scientific Advisor | $177,661.00 | — | — | $106,840.00 | 0.06% |
Brent Sabatini | Senior Vice President, Principal Accounting Officer & Chief Accounting Officer | — | — | 52 | $61,902.00 | 0.04% |
Jennifer Eileen Towne | Executive Vice President & Chief Scientific Officer | — | — | — | — | — |
Maninder Hora | Executive Vice President & Chief Technical Operations Officer | — | — | 72 | — | — |
Kiki Patel | Head of Investor Relations | — | — | — | — | — |
Carolyn Wang | Senior Vice President of Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
57
$21.39M
Net Sentiment
$21.39M
Net selling
Most Active
SVF Endurance (Cayman) Ltd
21 transactions
1–10 of 57
Analysis
Insiders reported 0 buys worth $0.00 and 57 sells worth $21.39M over the last 12 months. That adds up to net selling of $21.39M. SVF Endurance (Cayman) Ltd was the most active insider with 21 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +980.7% | -14.7% (9yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +980.7% over three years. Forward estimates point to Revenue at -14.7% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Geron Corporation
NASDAQ:GERN
$737.75M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
YD Bio Limited Ordinary Shares
NASDAQ:YDES
$231.62M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
Who manages VIR?
Vir Biotechnology, Inc. (VIR) lists 11 active executives. The top listed executive is Brent Sabatini, Senior Vice President, Principal Accounting Officer & Chief Accounting Officer.
Are VIR insiders buying or selling?
Recent insider activity shows net buying of $820,460.44.
Explore More
Continue the stock analysis
Jump to another research area for this company.